New Delhi [India], June 28 (ANI): The Drugs Controller General of India (DCGI) has given restricted emergency use authorisation (EUA) to Pune-based Serum Institute of India's COVID-19 vaccine 'Covovax' for children aged 7 to 12 years, sources told ANI.

Moscow [Russia], May 9 (ANI/Sputnik): Russian Health Minister Mikhail Murashko said on Monday that consultations with the World Health Organization (WHO) on approval of the Russian Sputnik V COVID-19 vaccine are still underway.

Pune (Maharashtra) [India], May 5 (ANI): Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

New Delhi [India], May 3 (ANI): Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the COVID-19 vaccine Covovax is now available in India for children.

New Delhi [India], April 30 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee on Friday sought more data from Pune based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years.

New Delhi Mar 30 PTI A Covid working group of NTAGI will review this week data of Serum Institute of Indias SII anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above official sources said on WednesdayIndias drug regulator had approved Covovaxfor restricted use in emergency situations in adults onDecember28and in the 12 to 17 years age group subject to certain conditions on March 9Director Government and Regulatory Affairs at SII Prakash Kumar Singh recently had written to the health ministry urging it to include Covovax in the national COVID-19 vaccination drive for 12 years and aboveSingh stated that the Pune-based firm wants to provide Covovax to private hospitals at Rs 900 per dose plus GST and is also waiting for directions to supply the vaccine to the Centre but has not mentioned the priceThe COVID-19working group of the NTAGI is set to meet on April 1 and review the data of Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above this week an official source saidIn a letter to Health Secretary Rajesh BhushanSingh was learnt to have said that private companies educational institutes social organisations central government organisations and public sector undertakings are making requests for Covovax to inoculate their staffers families and childrenUnder the visionary leadership of our CEO Adar C Poonawalla we have developed manufactured and obtained emergency use authorisation from our national regulatory authority for one more world-class COVID-19 vaccine Covovax for 18 years and above on December 28 and for children in the age group of 12 to 17 years on March 9 2022 an official source had quoted Singh as having said in the letter The country began inoculating children aged 12-14 from March 16 The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase Vaccination of frontline workers started from February 2 last yearThe next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions India launched vaccination for all people aged more than 45 years from April 1 last year The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last yearThe next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 yearsIndia began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10 PTI PLB ZMN

New Delhi [India], March 30 (ANI): The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine -- Covovax for use for children and adults, on April 1, sources informed on Wednesday.

New Delhi Mar 23 PTI The Drugs Controller General of India DCGI granted permission on Wednesday for conducting the phase-3 clinical trial of COVID-19 vaccine Covovax as a booster dose in adults official sources saidThe Subject Expert Committee SEC on COVID-19 of the Central Drugs Standard Control Organisation CDSCO had on March 5 recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose in adults who have been fully vaccinated with either Covaxin or Covishield at least three months agoThe DCGI approved Covovax for restricted use in emergency situations in adults on December 28 last year and for inoculating the beneficiaries in the 12-17 years age group subject to certain conditions on March 9The vaccine has not been included in the countrys inoculation programme against COVID-19Director Government and Regulatory Affairs at the Serum Institute of India SII Prakash Kumar Singh submitted an application to the DCGI in February seeking permission to conduct a phase-3 observer-blind randomised controlled study to evaluate the safety and immunogenicity of Covovax for booster doses in adults who had received primary vaccination either with Covishield or Covaxin at least three months ago an official source had saidSingh had stated that many countries were administering booster doses to their citizens considering the uncertainties of the pandemicWe are sure that your approval for conducting this clinical trial will ensure an early availability of Covovax for booster-dose use for the people of our country as well as the world at large in line with our prime ministers vision of Making in India for the WorldOur firm is committed to providing world-class life-saving vaccines at an affordable price under the visionary leadership of our CEO Dr Adar C Poonawalla We request you to kindly grant us permission to conduct a phase-3 clinical trial for booster dose of Covovaxin Indian adults he had stated in the applicationCovovax is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorisation It was granted emergency-use listing by the World Health Organization WHO in December 2020In August 2020 US-based vaccine-maker Novavax Inc had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373 its COVID-19 vaccine candidate in low-and-middle-income countries and in India PTI PLB RC

New Delhi [India], March 23 (ANI): Novavax on Tuesday announced the first emergency use authorization of its COVID-19 vaccine for adolescents falling in the age bracket of 12-18 years in India.

New Delhi [India], March 9 (ANI): The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation (EUA) to Serum Institute of India's (SII) COVID-19 vaccine Covovax for adults and for children above the age of 12 years.